業績・活動主要業績 | 広島大学大学院医系科学研究科消化器・代謝内科学

トップ >
業績・活動　主要業績

主要業績

2000年～2020年の20年間で、Impact Factor 7以上が135報!

掲載誌Impact Factor(2019)

New Engl J Med (1報)
74.699
Nat Med (1報)
36.13
Nat Rev Gastroenterol Hepatol (1報)
29.848
Nat Genet (7報)
27.603
Cancer Cell(1報)
26.602
Circulation (5報)
23.603
J Hepatol (20報)
20.852
J Am Coll Cardiol (8報)
20.589
Gut (6報)
19.819
Gastroenterology (12報)
17.373
Sci Transl Med (1報)
16.304
Diabetes Care(1報)
16.019
Nat Microbiol (1報)
15.54
Hepatology (24報)
14.679

掲載誌Impact Factor(2019)

Circulation Researce (1報)
14.467
Nat Commun (2報)
12.121
J Clin Invest (2報)
11.864
Genome Res(1報)
11.093
Biosens Bioelectron (1報)
10.257
Am J Gastroenterol (7報)
10.171
Clin Cancer Res (5報)
10.107
Cancer Res (3報)
9.727
Liver Cancer (1報)
9.72
Cancer Immunol Res(1報)
8.728
Radiology(1報)
7.931
Aliment Pharmacol Ther(12報)
7.515
Endoscopy (3報)
7.341
Gastric Cancer (6報)
7.088

Higashi Y. Sasaki S. Nakagawa K. Matsuura H. Oshima T, and Chayama K, Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002; 346: 1954-62.
Sainz B, Jr. Barretto N. Martin D N. Hiraga N. Imamura M. Hussain S. Marsh K A. Yu X. Chayama K. Alrefai W A, and Uprichard S L, Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.Nat Med. 2012; 18: 281-5.
Tsuge M. Hamamoto R. Silva F P. Ohnishi Y. Chayama K. Kamatani N. Furukawa Y, and Nakamura Y, A variable number of tandem repeats polymorphism in an E2F-1 binding element in the 5' flanking region of SMYD3 is a risk factor for human cancers. Nat Genet. 2005; 37: 1104-7.
Kamatani Y. Wattanapokayakit S. Ochi H. Kawaguchi T. Takahashi A. Hosono N. Kubo M. Tsunoda T. Kamatani N. Kumada H. Puseenam A. Sura T. Daigo Y. Chayama K. Chantratita W. Nakamura Y, and Matsuda K, A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet. 2009; 41: 591-5.
Miki D. Kubo M. Takahashi A. Yoon K A. Kim J. Lee G K. Zo J I. Lee J S. Hosono N. Morizono T. Tsunoda T. Kamatani N. Chayama K. Takahashi T. Inazawa J. Nakamura Y, and Daigo Y, Variation in TP63 is associated with lung adenocarcinoma susceptibility in Japanese and Korean populations. Nat Genet. 2010; 42: 893-6.
Miki D. Ochi H. Hayes C N. Abe H. Yoshima T. Aikata H. Ikeda K. Kumada H. Toyota J. Morizono T. Tsunoda T. Kubo M. Nakamura Y. Kamatani N, and Chayama K, Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers. Nat Genet. 2011; 43: 797-800.
Fujimoto A. Totoki Y. Abe T. Boroevich K A. Hosoda F. Nguyen H H. Aoki M. Hosono N. Kubo M. Miya F. Arai Y. Takahashi H. Shirakihara T. Nagasaki M. Shibuya T. Nakano K. Watanabe-Makino K. Tanaka H. Nakamura H. Kusuda J. Ojima H. Shimada K. Okusaka T. Ueno M. Shigekawa Y. Kawakami Y. Arihiro K. Ohdan H. Gotoh K. Ishikawa O. Ariizumi S. Yamamoto M. Yamada T. Chayama K. Kosuge T. Yamaue H. Kamatani N. Miyano S. Nakagama H. Nakamura Y. Tsunoda T. Shibata T, and Nakagawa H, Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012; 44: 760-4.
Fujimoto A, Furuta M, Totoki Y, Tsunoda T, Kato M, Shiraishi Y, Tanaka H, Taniguchi H, Kawakami Y, Ueno M, Gotoh K, Ariizumi S, Wardell CP, Hayami S, Nakamura T, Aikata H, Arihiro K, Boroevich KA, Abe T, Nakano K, Maejima K, Sasaki-Oku A, Ohsawa A, Shibuya T, Nakamura H, Hama N, Hosoda F, Arai Y, Ohashi S, Urushidate T, Nagae G, Yamamoto S, Ueda H, Tatsuno K, Ojima H, Hiraoka N, Okusaka T, Kubo M, Marubashi S, Yamada T, Hirano S, Yamamoto M, Ohdan H, Shimada K, Ishikawa O, Yamaue H, Chayama K, Miyano S, Aburatani H, Shibata T, Nakagawa H. Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer. Nat Genet. 2016; 48: 500-9.
Ishigaki K, Akiyama M, Kanai M, Takahashi A, Kawakami E, Sugishita H, Sakaue S, Matoba N, Low SK, Okada Y, Terao C, Amariuta T, Gazal S,Kochi Y, Horikoshi M, Suzuki K, Ito K, Koyama S,Ozaki K, Niida S, Sakata Y, Sakata Y, Kohno T, Shiraishi K, Momozawa Y, Hirata M, Matsuda K, Ikeda M, Iwata N, Ikegawa S, Kou I,Tanaka T, Nakagawa H, Suzuki A, Hirota T, Tamari M,Chayama K, Miki D, Mori M, Nagayama S, Daigo Y, Miki Y, Katagiri T, Ogawa O, Obara W, Ito H, Yoshida T, Imoto I, Takahashi T, Tanikawa C, Suzuki T, Sinozaki N, Minami S, Yamaguchi H, Asai S, Takahashi Y, Yamaji K,Takahashi K, Fujioka T, Takata R, Yanai H, Masumoto A, Koretsune Y, Kutsumi H,Higashiyama M, Murayama S, Minegishi N, Suzuki K, Tanno K, Shimizu A, Yamaji T, Iwasaki M, Sawada N, Uemura H, Tanaka K, Naito M, Sasaki M, Wakai K, Tsugane S, Yamamoto M, Yamamoto K, Murakami Y,Nakamura Y, Raychaudhuri S, Inazawa J, Yamauchi T, Kadowaki T, Kubo M and Kamatani Y. Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases. Nat Genet. 2020; 52:669-679.
Xue R, Chen L, Zhang C, Fujita M, Li R, Yan SM, Ong CK, Liao X, Gao Q, Sasagawa S, Li Y, Wang J, Guo H, Huang QT, Zhong Q, Tan J, Qi L, Gong W, Hong Z, Li M, Zhao J, Peng T, Lu Y, Lim KHT, Boot A, Ono A, Chayama K, Zhang Z, Rozen SG, Teh BT, Wang XW, Nakagawa H, Zeng MS, Bai F and Zhang N.Genomic and Transcriptomic Profiling of Combined Hepatocellular and Intrahepatic Cholangiocarcinoma Reveals Distinct Molecular Subtypes. Cancer Cell. 2019; 35: 932-947.e8.
Hayes C N. Imamura M. Aikata H, and Chayama K, Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol. 2012; 9: 406-417.
Higashi Y, Sasaki S, Kurisu S, Yoshimizu A, Sasaki N, Matsuura H, Kajiyama G, Oshima T. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. Circulation. 2000; 100: 1194-202.
Goto C. Higashi Y. Kimura M. Noma K. Hara K. Nakagawa K. Kawamura M. Chayama K. Yoshizumi M, and Nara I, Effect of different intensities of exercise on endothelium-dependent vasodilation in humans: role of endothelium-dependent nitric oxide and oxidative stress. Circulation. 2003; 108: 530-5.
Higashi Y. Kimura M. Hara K. Noma K. Jitsuiki D. Nakagawa K. Oshima T. Chayama K. Sueda T. Goto C. Matsubara H. Murohara T, and Yoshizumi M, Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation. 2004; 109: 1215-8.
Fujii Y. Nishioka K. Yoshizumi M. Chayama K, and Higashi Y, Images in cardiovascular medicine. Corkscrew collaterals in thromboangitis obliterans (Buerger's disease). Circulation. 2007; 116: e539-40.
Maruhashi T. Soga J. Fujimura N. Idei N. Mikami S. Iwamoto Y. Kajikawa M. Matsumoto T. Kihara Y. Chayama K. Noma K. Nakashima A. Tomiyama H. Takase B. Yamashina A, and Higashi Y, Hyperbilirubinemia, augmentation of endothelial function, and decrease in oxidative stress in Gilbert syndrome. Circulation. 2012; 126: 598-603.
Imamura M. Ogawa T. Sasaguri Y. Chayama K, and Ueno H, Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. Gastroenterology. 2005; 128: 138-46.
Soetikno R. Friedland S. Kaltenbach T. Chayama K, and Tanaka S, Nonpolypoid (flat and depressed) colorectal neoplasms. Gastroenterology. 2006; 130: 566-76; quiz 588-9.
Yamamoto H. Kitadai Y. Yamamoto H. Oue N. Ohdan H. Yasui W, and Kikuchi A, Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. Gastroenterology. 2009; 137: 242-52, 252.e1-6.
Matsumura T. Hu Z. Kato T. Dreux M. Zhang Y Y. Imamura M. Hiraga N. Juteau J M. Cosset F L. Chayama K. Vaillant A, and Liang T J, Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry. Gastroenterology. 2009; 137: 673-81.
Tsukada H. Ochi H. Maekawa T. Abe H. Fujimoto Y. Tsuge M. Takahashi H. Kumada H. Kamatani N. Nakamura Y, and Chayama K, A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C. Gastroenterology. 2009; 136: 1796-805 e6.
Ochi H. Maekawa T. Abe H. Hayashida Y. Nakano R. Kubo M. Tsunoda T. Hayes C N. Kumada H. Nakamura Y, and Chayama K, ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology. 2010; 139: 1190-7.
Wakita T. Suzuki T. Evans M J. Shimotohno K. Chayama K. Matsuura Y. Hijikata M. Moriishi K. Seya T. Enomoto N. Koike K. Kato N. Kanto T, and Hotta H, Will there be an HCV meeting in 2020? Summary of the 17th international meeting on hepatitis C virus and related viruses. Gastroenterology. 2011; 141: e1-5.
Hewett D G. Kaltenbach T. Sano Y. Tanaka S. Saunders B P. Ponchon T. Soetikno R, and Rex D K, Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology. 2012; 143: 599-607 e1.
Abe Y. Aly H H. Hiraga N. Imamura M. Wakita T. Shimotohno K. Chayama K, and Hijikata M, Thromboxane A2 synthase inhibitors prevent production of infectious hepatitis C virus in mice with humanized livers. Gastroenterology. 2013; 145: 658-67 e11.
Soetikno R. Subramanian V. Kaltenbach T. Rouse R V. Sanduleanu S. Suzuki N. Tanaka S, and McQuaid K, The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013; 144: 1349-52, 1352 e1-6.
Lupberger J, Croonenborghs T, Roca Suarez AA, Van Renne N, Juhling F, Oudot MA, Virzi A, Bandiera S, Jamey C, Meszaros G, Brumaru D, Mukherji A, Durand SC, Heydmann L, Verrier ER, El Saghire H, Hamdane N, Bartenschlager R, Fereshetian S, Ramberger E, Sinha R, Nabian M, Everaert C, Jovanovic M, Mertins P, Carr SA, Chayama K, Dali-Youcef N, Ricci R, Bardeesy NM, Fujiwara N, Gevaert O, Zeisel MB, Hoshida Y, Pochet N and Baumert TF.Combined Analysis of Metabolomes, Proteomes, and Transcriptomes of HCV-infected Cells and Liver to Identify Pathways Associated With Disease Development. Gastroenterology. 2019; In Press.
Hamdane N, Juhling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoel M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT and Baumert TF. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology. 2019; 156: 2313-2329e2317.
Tanaka Y. Hanada K. Orito E. Akahane Y. Chayama K. Yoshizawa H. Sata M. Ohta N. Miyakawa Y. Gojobori T, and Mizokami M, Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatol. 2005; 42: 47-53.
Hiraga N. Imamura M. Hatakeyama T. Kitamura S. Mitsui F. Tanaka S. Tsuge M. Takahashi S. Abe H. Maekawa T. Ochi H. Tateno C. Yoshizato K. Wakita T, and Chayama K, Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice. J Hepatol. 2009; 51: 1046-54.
Nabeshima Y. Tazuma S. Kanno K. Hyogo H, and Chayama K, Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol. 2009; 50: 1226-35.
Abe H. Ochi H. Maekawa T. Hayes C N. Tsuge M. Miki D. Mitsui F. Hiraga N. Imamura M. Takahashi S. Ohishi W. Arihiro K. Kubo M. Nakamura Y, and Chayama K, Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol. 2010; 53: 439-43.
Yokosuka O. Takaguchi K. Fujioka S. Shindo M. Chayama K. Kobashi H. Hayashi N. Sato C. Kiyosawa K. Tanikawa K. Ishikawa H. Masaki N. Seriu T, and Omata M, Long-term use of entecavir in nucleoside-naive Japanese patients with chronic hepatitis B infection. J Hepatol. 2010; 52: 791-9.
Abe H. Imamura M. Hiraga N. Tsuge M. Mitsui F. Kawaoka T. Takahashi S. Ochi H. Maekawa T. Hayes C N. Tateno C. Yoshizato K. Murakami S. Yamashita N. Matsuhira T. Asai K, and Chayama K, ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo. J Hepatol. 2011; 55: 11-18.
Abe H. Hayes C N. Ochi H. Maekawa T. Tsuge M. Miki D. Mitsui F. Hiraga N. Imamura M. Takahashi S. Kubo M. Nakamura Y, and Chayama K, IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol. 2011; 54: 1094-101.
Ohara E. Hiraga N. Imamura M. Iwao E. Kamiya N. Yamada I. Kono T. Onishi M. Hirata D. Mitsui F. Kawaoka T. Tsuge M. Takahashi S. Abe H. Hayes C N. Ochi H. Tateno C. Yoshizato K. Tanaka S, and Chayama K, Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J Hepatol. 2011; 54: 872-8.
Kawaoka T. Hayes C N. Ohishi W. Ochi H. Maekawa T. Abe H. Tsuge M. Mitsui F. Hiraga N. Imamura M. Takahashi S. Kubo M. Tsunoda T. Nakamura Y. Kumada H, and Chayama K, Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol. 2011; 54: 408-14.
Fujimoto Y, Ochi H, Maekawa T, Abe H, Hayes CN, Kumada H, Nakamura Y, Chayama K. A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients. J Hepatol. 2011; 54: 629-39.
Ono A. Suzuki F. Kawamura Y. Sezaki H. Hosaka T. Akuta N. Kobayashi M. Suzuki Y. Saitou S. Arase Y. Ikeda K. Kobayashi M. Watahiki S. Mineta R, and Kumada H, Long-term continuous entecavir therapy in nucleos(t)ide-naive chronic hepatitis B patients. J Hepatol. 2012; 57: 508-14.
Kumada H. Toyota J. Okanoue T. Chayama K. Tsubouchi H, and Hayashi N, Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012; 56: 78-84.
Urabe Y. Ochi H. Kato N. Kumar V. Takahashi A. Muroyama R. Hosono N. Otsuka M. Tateishi R. Lo P H. Tanikawa C. Omata M. Koike K. Miki D. Abe H. Kamatani N. Toyota J. Kumada H. Kubo M. Chayama K. Nakamura Y, and Matsuda K, A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region. J Hepatol. 2013; 58: 875-82.
Suzuki Y. Ikeda K. Suzuki F. Toyota J. Karino Y. Chayama K. Kawakami Y. Ishikawa H. Watanabe H. Hu W. Eley T. McPhee F. Hughes E, and Kumada H, Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013; 58: 655-62.
Karino Y. Toyota J. Ikeda K. Suzuki F. Chayama K. Kawakami Y. Ishikawa H. Watanabe H. Hernandez D. Yu F. McPhee F, and Kumada H, Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013; 58: 646-54.
Akamatsu S, Hayes CN, Ochi H, Uchida T, Kan H, Murakami E, Abe H, Tsuge M, Miki D, Akiyama R, Hiraga N, Imamura M, Aikata H, Kawaoka T, Kawakami Y, Chayama K. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A. J Hepatol. 2015; 63: 554-563.
Yamamoto N, Sato Y, Munakata T, Kakuni M, Tateno C, Sanada T, Hirata Y, Murakami S, Tanaka Y, Chayama K, Hatakeyama H, Hyodo M, Harashima H, Kohara M. Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection. J Hepatol. 2016; 64: 547-55.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Jung KS, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V, Wiegand J. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017; 66: 1022-1030.
Furuta M, Ueno M, Fujimoto A, Hayami S, Yasukawa S, Kojima F, Arihiro K, Kawakami Y, Wardell CP, Shiraishi Y, Tanaka H, Nakano K, Maejima K, Sasaki-Oku A, Tokunaga N, Boroevich KA, Abe T, Aikata H, Ohdan H, Gotoh K, Kubo M, Tsunoda T, Miyano S, Chayama K, Yamaue H, Nakagawa H. Whole genome sequencing discriminates hepatocellular carcinoma with intrahepatic metastasis from multi-centric tumors. J Hepatol. 2017; 66: 363-373.
Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K, Lawlor RT, Nakanishi Y, Mitsuhashi T, Fujimoto A, Furuta M, Ruzzenente A, Conci S, Oosawa A, Sasaki-Oku A, Nakano K, Tanaka H, Yamamoto Y, Michiaki K, Kawakami Y, Aikata H, Ueno M, Hayami S, Gotoh K, Ariizumi SI, Yamamoto M, Yamaue H, Chayama K, Miyano S, Getz G, Scarpa A, Hirano S, Nakamura T and Nakagawa H. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018; 68: 959-969.
Higashi Y. Sasaki S. Nakagawa K. Ueda T. Yoshimizu A. Kurisu S. Matsuura H. Kajiyama G, and Oshima T, A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol. 2000; 35: 284-91.
Sanada M. Higashi Y. Nakagawa K. Sasaki S. Kodama I. Tsuda M. Nagai N, and Ohama K, Relationship between the angiotensin-converting enzyme genotype and the forearm vasodilator response to estrogen replacement therapy in postmenopausal women. J Am Coll Cardiol. 2001; 37: 1529-35.
Higashi Y. Sasaki S. Nakagawa K. Matsuura H. Kajiyama G, and Oshima T, Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol. 2001; 37: 863-70.
Higashi Y. Nakagawa K. Kimura M. Noma K. Hara K. Sasaki S. Goto C. Oshima T. Chayama K, and Yoshizumi M, Circadian variation of blood pressure and endothelial function in patients with essential hypertension:a comparison of dippers and non-dippers. J Am Coll Cardiol. 2002; 40: 2039-43.
Higashi Y. Sasaki S. Nakagawa K. Kimura M. Noma K. Hara K. Matsuura H. Goto C. Oshima T. Chayama K, and Yoshizumi M, Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress. J Am Coll Cardiol. 2003; 42: 256-63.
Nakano Y. Niida S. Dote K. Takenaka S. Hirao H. Miura F. Ishida M. Shingu T. Sueda T. Yoshizumi M, and Chayama K, Matrix metalloproteinase-9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol. 2004; 43: 818-25.
Oshima T. Ozono R. Yano Y. Oishi Y. Teragawa H. Higashi Y. Yoshizumi M, and Kambe M, Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol. 2005; 45: 1219-22.
Noma K. Goto C. Nishioka K. Jitsuiki D. Umemura T. Ueda K. Kimura M. Nakagawa K. Oshima T. Chayama K. Yoshizumi M. Liao J K, and Higashi Y, Roles of rho-associated kinase and oxidative stress in the pathogenesis of aortic stiffness. J Am Coll Cardiol. 2007; 49: 698-705.
Hayes C N. Kobayashi M. Akuta N. Suzuki F. Kumada H. Abe H. Miki D. Imamura M. Ochi H. Kamatani N. Nakamura Y, and Chayama K, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011; 60: 261-7.
Nakamura S. Sugiyama T. Matsumoto T. Iijima K. Ono S. Tajika M. Tari A. Kitadai Y. Matsumoto H. Nagaya T. Kamoshida T. Watanabe N. Chiba T. Origasa H. Asaka M, and Group J G S, Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012; 61: 507-13.
Shi N. Hiraga N. Imamura M. Hayes C N. Zhang Y. Kosaka K. Okazaki A. Murakami E. Tsuge M. Abe H. Aikata H. Takahashi S. Ochi H. Tateno-Mukaidani C. Yoshizato K. Matsui H. Kanai A. Inaba T. McPhee F. Gao M, and Chayama K, Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Gut. 2013; 62: 1055-61.
Ishikawa H MM, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial. Gut. 2014; 63: 1755-1759.
Van Renne N, Roca Suarez AA, Duong FHT, Gondeau C, Calabrese D, Fontaine N, Ababsa A, Bandiera S, Croonenborghs T, Pochet N, De Blasi V, Pessaux P, Piardi T, Sommacale D, Ono A, Chayama K, Fujita M, Nakagawa H, Hoshida Y, Zeisel MB, Heim MH, Baumert TF and Lupberger J. miR-135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCV-associated hepatocarcinogenesis. Gut. 2018; 67: 953-962.
Juhling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A,Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C,Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC and Baumert TF. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut. 2020; 0:1-13.
He S, Lin B, Chu V, Hu Z, Hu X, Xiao J, Wang AQ, Schweitzer CJ, Li Q, Imamura M, Hiraga N, Southall N, Ferrer M, Zheng W, Chayama K, Marugan JJ, Liang TJ. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Sci Transl Med. 2015; 7: 282ra249.
Ishida M. Ishida T. Nakashima H. Miho N. Miyagawa K. Chayama K. Oshima T. Kambe M, and Yoshizumi M, Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells. Circ Res. 2003; 93: 1218-24.
Kajikawa M, Nakashima A, Fujimura N, Maruhashi T, Iwamoto Y, Iwamoto A, Matsumoto T, Oda N, Hidaka T, Kihara Y, Chayama K, Goto C, Aibara Y, Noma K, Takeuchi M, Matsui T, Yamagishi S, Higashi Y. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015; 38: 119-25.
Ma CD, Imamura M, Talley DC, Rolt A, Xu X, Wang AQ, Le D, Uchida T, Osawa M,Teraoka Y, Li K, Hu X, Park SB, Chalasani N, Irvin PH, Dulcey AE, Southall N,Marugan JJ, Hu Z, Chayama K, Frankowski KJ, Liang TJ.Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nat Microbiol. 2020. In Press.
Chayama K. Suzuki F. Tsubota A. Kobayashi M. Arase Y. Saitoh S. Suzuki Y. Murashima N. Ikeda K. Takahashi N. Kinoshita M, and Kumada H, Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy. Hepatology. 2000; 32: 1138-44.
Ikeda K. Arase Y. Saitoh S. Kobayashi M. Suzuki Y. Suzuki F. Tsubota A. Chayama K. Murashima N, and Kumada H, Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000; 32: 228-32.
Tsuge M. Hiraga N. Takaishi H. Noguchi C. Oga H. Imamura M. Takahashi S. Iwao E. Fujimoto Y. Ochi H. Chayama K. Tateno C, and Yoshizato K, Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology. 2005; 42: 1046-54.
Noguchi C. Ishino H. Tsuge M. Fujimoto Y. Imamura M. Takahashi S, and Chayama K, G to A hypermutation of hepatitis B virus. Hepatology. 2005; 41: 626-33.
Hatakeyama T. Noguchi C. Hiraga N. Mori N. Tsuge M. Imamura M. Takahashi S. Kawakami Y. Fujimoto Y. Ochi H. Abe H. Maekawa T. Kawakami H. Yatsuji H. Aisaka Y. Kohno H. Aimitsu S, and Chayama K, Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology. 2007; 45: 1179-86.
Utoh R. Tateno C. Yamasaki C. Hiraga N. Kataoka M. Shimada T. Chayama K, and Yoshizato K, Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus. Hepatology. 2008; 47: 435-46.
Akuta N. Suzuki F. Hirakawa M. Kawamura Y. Yatsuji H. Sezaki H. Suzuki Y. Hosaka T. Kobayashi M. Kobayashi M. Saitoh S. Arase Y. Ikeda K. Chayama K. Nakamura Y, and Kumada H, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010; 52: 421-9.
Hiraga N. Imamura M. Abe H. Hayes C N. Kono T. Onishi M. Tsuge M. Takahashi S. Ochi H. Iwao E. Kamiya N. Yamada I. Tateno C. Yoshizato K. Matsui H. Kanai A. Inaba T. Tanaka S, and Chayama K, Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology. 2011; 54: 781-8.
Hiraga N. Abe H. Imamura M. Tsuge M. Takahashi S. Hayes C N. Ochi H. Tateno C. Yoshizato K. Nakamura Y. Kamatani N, and Chayama K, Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011; 54: 764-71.
Saeed M. Shiina M. Date T. Akazawa D. Watanabe N. Murayama A. Suzuki T. Watanabe H. Hiraga N. Imamura M. Chayama K. Choi Y. Krawczynski K. Liang T J. Wakita T, and Kato T, In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology. 2011; 54: 425-33.
Ohishi W. Fujiwara S. Cologne J B. Suzuki G. Akahoshi M. Nishi N. Tsuge M, and Chayama K, Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology. 2011; 53: 1237-45.
Suzuki F. Suzuki Y. Akuta N. Sezaki H. Hirakawa M. Kawamura Y. Hosaka T. Kobayashi M. Saito S. Arase Y. Ikeda K. Kobayashi M. Chayama K. Kamatani N. Nakamura Y. Miyakawa Y, and Kumada H, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology. 2011; 53: 415-21.
Okazaki A. Hiraga N. Imamura M. Hayes C N. Tsuge M. Takahashi S. Aikata H. Abe H. Miki D. Ochi H. Tateno C. Yoshizato K. Ohdan H, and Chayama K, Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse. Hepatology. 2012; 56: 555-66.
Chayama K. Takahashi S. Toyota J. Karino Y. Ikeda K. Ishikawa H. Watanabe H. McPhee F. Hughes E, and Kumada H, Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012; 55: 742-8.
Abe H, Hayes CN, Chayama K. New insight into the enhanced effect of pegylated interferon-alpha. Hepatology. 2014; 60: 1435-1437.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014; 59: 2083-2091.
Chayama K, Notsumata K, Kurosaki M, Sato K, Rodrigues L, Jr., Setze C, Badri P, Pilot-Matias T, Vilchez RA, Kumada H. Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Hepatology. 2015; 61: 1523-1532.
Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Mori K, Tanaka S, Yamada M, Akita M, Mizutani K, Fujii H, Yamamoto A, Takamatsu S, Yoshida Y, Itoh Y, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E. A novel noninvasive diagnostic method for nonalcoholic steatohepatitis using two glycobiomarkers. Hepatology. 2015; 62: 1433-1443.
Kumada H, Chayama K, Rodrigues L, Jr., Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015; 62: 1037-1046.
Abe-Chayama H, Hayes CN, Chayama K. Pan-genotypic cell culture system for propagation of hepatitis C virus clinical isolates. Hepatology. 2016; 64: 1356-8.
Cheng X, Xia Y, Serti E, Block PD, Chung M, Chayama K, Rehermann B and Liang TJ. Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology. 2017; 66: 1779-1793.
Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B and Kumada H. Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection. Hepatology. 2018;67: 505-513.
Ishida Y, Chung TL, Imamura M, Hiraga N, Sen S, Yokomichi H, Tateno C, Canini L, Perelson AS, Uprichard SL, Dahari H and Chayama K. Acute hepatitis B infection in humanized chimeric mice has multiphasic viral kinetics. Hepatology. 2018; 68: 473-484
Johira Y, Hatooka H, Mori N, Fukuhara T, Takaki S, Shimomura Y,Imamura M, Hayes CN, Tsuji K and Chayama K. Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals. Hepatology. 2020; 71: 389-391.
Ohira M. Ishiyama K. Tanaka Y. Doskali M. Igarashi Y. Tashiro H. Hiraga N. Imamura M. Sakamoto N. Asahara T. Chayama K, and Ohdan H, Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice. J Clin Invest. 2009; 119: 3226-35.
Cheng X, Uchida T, Xia Y, Umarova R, Liu CJ,Chen PJ, Gaggar A, Suri V, Mucke MM, Vermehren J, Zeuzem S, Teraoka Y, Osawa M, Aikata H, Tsuji K, Mori N, Hige S, Karino Y, Imamura M, Chayama K and Liang TJ.Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. J Clin Invest. 2020; 130:3205-3220.
Fujimoto A, Furuta M, Shiraishi Y, Gotoh K, Kawakami Y, Arihiro K, Nakamura T, Ueno M, Ariizumi S, Nguyen HH, Shigemizu D, Abe T, Boroevich KA, Nakano K, Sasaki A, Kitada R, Maejima K, Yamamoto Y, Tanaka H, Shibuya T, Shibata T, Ojima H, Shimada K, Hayami S, Shigekawa Y, Aikata H, Ohdan H, Marubashi S, Yamada T, Kubo M, Hirano S, Ishikawa O, Yamamoto M, Yamaue H, Chayama K, Miyano S, Tsunoda T, Nakagawa H. Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity. Nat Commun. 2015; 6: 6120.
Aizawa S, Okamoto T, Sugiyama Y, Kouwaki T, Ito A, Suzuki T, Ono C, Fukuhara T, Yamamoto M, Okochi M, Hiraga N, Imamura M, Chayama K, Suzuki R, Shoji I, Moriishi K, Moriya K, Koike K, Matsuura Y. TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis. Nat Commun. 2016; 7: 11379.
Locke C R, 3rd. Talley N J. Nelson D K. Haruma K. Weaver A L. Zinsmeister A R, and Melton L J, 3rd, Helicobacter pylori and dyspepsia: a population-based study of the organism and host. Am J Gastroenterol. 2000; 95: 1906-13.
Tsubota A. Arase Y. Saitoh S. Kobayashi M. Suzuki Y. Suzuki F. Chayama K. Murashima N. Ikeda K, and Kumada H, Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am J Gastroenterol. 2001; 96: 557-62.
Sasao S. Hiyama T. Tanaka S. Mukai S. Yoshihara M, and Chayama K, Medical malpractice litigation in gastroenterological practice in Japan: a 22-yr review of civil court cases. Am J Gastroenterol. 2006; 101: 1951-3.
Hiyama T. Yoshihara M. Tanaka S, and Chayama K, Trend in Japanese malpractice litigation involving gastrointestinal endoscopy. Am J Gastroenterol. 2009; 104: 251-2.
Hiyama T. Yoshihara M. Tanaka S, and Chayama K, Change in malpractice claims in Japanese gastroenterological practice. Am J Gastroenterol. 2012; 107: 143-4.
Abe H. Hayes C N. Hiraga N. Imamura M. Tsuge M. Miki D. Takahashi S. Ochi H, and Chayama K, A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing. Am J Gastroenterol. 2013; 108: 1464-72.
Oka S, Tanaka S, Saito Y, Iishi H, Kudo SE, Ikematsu H, Igarashi M, Saitoh Y, Inoue Y, Kobayashi K, Hisabe T, Tsuruta O, Sano Y, Yamano H, Shimizu S, Yahagi N, Watanabe T, Nakamura H, Fujii T, Ishikawa H, Sugihara K. Local recurrence after endoscopic resection for large colorectal neoplasia: a multicenter prospective study in Japan. Am J Gastroenterol. 2015; 110: 697-707.
Hiragun T. Yanase Y. Kose K. Kawaguchi T. Uchida K. Tanaka S, and Hide M, Surface plasmon resonance-biosensor detects the diversity of responses against epidermal growth factor in various carcinoma cell lines. Biosens Bioelectron. 2012; 32: 202-7.
Yokoi K. Sasaki T. Bucana C D. Fan D. Baker C H. Kitadai Y. Kuwai T. Abbruzzese J L, and Fidler I J, Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model. Cancer Res. 2005; 65: 10371-80.
Yang L. Avila H. Wang H. Trevino J. Gallick G E. Kitadai Y. Sasaki T, and Boyd D D, Plasticity in urokinase-type plasminogen activator receptor (uPAR) display in colon cancer yields metastable subpopulations oscillating in cell surface uPAR density--implications in tumor progression. Cancer Res. 2006; 66: 7957-67.
Nakamura T. Kuwai T. Kitadai Y. Sasaki T. Fan D. Coombes K R. Kim S J, and Fidler I J, Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res. 2007; 67: 7597-604.
Kitadai Y. Haruma K. Mukaida N. Ohmoto Y. Matsutani N. Yasui W. Yamamoto S. Sumii K. Kajiyama G. Fidler I J, and Tahara E, Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8. Clin Cancer Res. 2000; 6: 2735-40.
Kuniyasu H. Ohmori H. Sasaki T. Sasahira T. Yoshida K. Kitadai Y, and Fidler I J, Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia, angiogenesis, and metastasis. Clin Cancer Res. 2003; 9: 4802-10.
Kuroda T. Kitadai Y. Tanaka S. Yang X. Mukaida N. Yoshihara M, and Chayama K, Monocyte chemoattractant protein-1 transfection induces angiogenesis and tumorigenesis of gastric carcinoma in nude mice via macrophage recruitment. Clin Cancer Res. 2005; 11: 7629-36.
Kodama M. Kitadai Y. Tanaka M. Kuwai T. Tanaka S. Oue N. Yasui W, and Chayama K, Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin Cancer Res. 2008; 14: 7205-14.
Hirata D. Yamabuki T. Miki D. Ito T. Tsuchiya E. Fujita M. Hosokawa M. Chayama K. Nakamura Y, and Daigo Y, Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res. 2009; 15: 256-66.
Tanimine N, Tanaka Y, Kobayashi T, Tashiro H, Miki D, Imamura M, Aikata H, Tanaka J, Chayama K, Ohdan H. Quantitative effect of natural killer-cell licensing on hepatocellular carcinoma recurrence after curative hepatectomy. Cancer Immunol Res. 2014; 2: 1142-7.
Boot A, Huang MN, Ng AWT, Ho SC, Lim JQ, Kawakami Y, Chayama K, Teh BT, Nakagawa H and Rozen SG. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Res. 2018; 28: 654-665.
Ito M, Haruma K, Kamada T, Mihara M, Kim S, Kitadai Y, Sumii M, Tanaka S, Yoshihara M and Chayama K. Helicobacter pylori eradication therapy improves atrophic gastritis and intestinal metaplasia: a 5-year prospective study of patients with atrophic gastritis. Aliment Pharmacol Ther. 2002; 16: 1449-1456.
Ito M, Tanaka S, Kim S, Kuwai T, Matsutani N, Kamada T, Kitadai Y, Sumii M, Yoshihara M, Haruma K and Chayama K. The specific expression of hypoxia inducible factor-1alpha in human gastric mucosa induced by nonsteroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003; 18: 90-98.
Sasaki A, Haruma K, Manabe N, Tanaka S, Yoshihara M and Chayama K. Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2003; 17: 1529-1534.
Kai H, Ito M, Kitadai Y, Tanaka S, Haruma K and Chayama K. Chronic gastritis with expression of inducible nitric oxide synthase is associated with high expression of interleukin-6 and hypergastrinaemia. Aliment Pharmacol Ther. 2004; 19: 1309-1314.
Kamada T, Hata J, Kusunoki H, Sugiu K, Ito M, Tanaka S, Kawamura Y, Chayama K and Haruma K. Effect of long-term half-dose famotidine therapy on corpus gastritis in peptic ulcer disease. Aliment Pharmacol Ther. 2005; 21: 99-104.
Kamada T, Hata J, Kusunoki H, Kido S, Hamada H, Aoki R, Nishida T, Komoto K, Todo H, Sumioka M, Tanimoto T, Sanuki E, Sumii K, Ogoshi H, Hidaka T, Dongmei Q, Chayama K and Haruma K. Effect of famotidine on recurrent bleeding after successful endoscopic treatment of bleeding peptic ulcer. Aliment Pharmacol Ther. 2005; 21: 73-78.
Kamada T, Hata J, Sugiu K, Kusunoki H, Ito M, Tanaka S, Inoue K, Kawamura Y, Chayama K and Haruma K. Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori: results from a 9-year prospective follow-up study in Japan. Aliment Pharmacol Ther. 2005; 21: 1121-1126.
Ito M, Tanaka S, Takata S, Oka S, Imagawa S, Ueda H, Egi Y, Kitadai Y, Yasui W, Yoshihara M, Haruma K and Chayama K. Morphological changes in human gastric tumours after eradication therapy of Helicobacter pylori in a short-term follow-up. Aliment Pharmacol Ther. 2005; 21: 559-566.
Yamaguchi T, Manabe N, Hata J, Tanaka S, Haruma K and Chayama K. The usefulness of transabdominal ultrasound for the diagnosis of lower gastrointestinal bleeding. Aliment Pharmacol Ther. 2006; 23: 1267-1272.
Yokoyama S, Kawakami Y and Chayama K. Letter: Pitavastatin supplementation of PEG-IFN/ribavirin improves sustained virological response against HCV. Aliment Pharmacol Ther. 2014; 39: 443-444.
Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, Kumar M, Lupsor-Platon M, Han KH, Cardoso AC, Ferraioli G, Chan WK, Wong VW, Myers RP, Chayama K, Friedrich-Rust M, Beaugrand M, Shen F, Hiriart JB, Sarin SK, Badea R, Lee HW, Marcellin P, Filice C, Mahadeva S, Wong GL, Crotty P, Masaki K, Bojunga J, Bedossa P, Keim V and Wiegand J. Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther. 2018; 47: 989-1000.
Kumada T,Toyoda H, Yasuda S, Tada T, Ogawa S, Takeshima K, Tanaka J, Chayama K and Johnson PJ. Impact of the introduction of direct-acting anti-viral drugs on hepatocarcinogenesis: a prospective serial follow-up MRI study. Aliment Pharmacol Ther .2020; In Press.
Okanobu, H. Hata, J. Haruma, K. Hara, M. Nakamura, K. Tanaka, S. Chayama, K. Giant gastric folds: differential diagnosis at US. Radiology. 2003; 226: 686-90.
Uchikawa S, Kawaoka T, Namba M, Kodama K, Ohya K, Morio K, Nakahara T, Murakami E, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Chayama K and Aikata H. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients. Liver Cancer. Liver Cancer.2020; 9: 148-155.
Oka S, Tanaka S, Kaneko I, Mouri R, Hirata M, Kanao H, Kawamura T, Yoshida S, Yoshihara M and Chayama K. Endoscopic submucosal dissection for residual/local recurrence of early gastric cancer after endoscopic mucosal resection. Endoscopy.2006; 38: 996-1000.
Kodama M, Kitadai Y, Shishido T, Shimamoto M, Fukumoto A, Masuda H, Tanaka S, Yoshihara M, Sakai A, Nakayama H and Chayama K. Primary follicular lymphoma of the gastrointestinal tract: a retrospective case series. Endoscopy.2008; 40: 343-346.
Urabe Y, Hiyama T, Tanaka S, Oka S, Yoshihara M, Arihiro K and Chayama K. Metachronous multiple esophageal squamous cell carcinomas and Lugol-voiding lesions after endoscopic mucosal resection. Endoscopy.2009; 41: 304-309.
Sanomura Y, Oka S, Tanaka S, Noda I, Higashiyama M, Imagawa H, Shishido T, Yoshida S, Hiyama T, Arihiro K and Chayama K. Clinical validity of endoscopic submucosal dissection for submucosal invasive gastric cancer: a single-center study. Gastric Cancer.2012; 15: 97-105.
Higashimaya M, Oka S, Tanaka S, Sanomura Y, Yoshida S, Hiyama T, Arihiro K, Shimamoto F and Chayama K. Outcome of endoscopic submucosal dissection for gastric neoplasm in relationship to endoscopic classification of submucosal fibrosis. Gastric Cancer.2013; 16: 404-410.
Sanomura Y, Oka S, Tanaka S, Numata N, Higashiyama M, Kanao H, Yoshida S, Ueno Y and Chayama K. Continued use of low-dose aspirin does not increase the risk of bleeding during or after endoscopic submucosal dissection for early gastric cancer. Gastric Cancer.2014; 17: 489-496.
Numata N, Oka S, Tanaka S, Kagemoto K, Sanomura Y, Yoshida S, Arihiro K, Shimamoto F and Chayama K. Risk factors and management of positive horizontal margin in early gastric cancer resected by en bloc endoscopic submucosal dissection. Gastric Cancer.2015; 18: 332-338.
Yoshifuku Y, Sanomura Y, Oka S, Tanaka S and Chayama K. Investigation of each histological type in undifferentiated early gastric cancer and validity of diagnosis of the disease range. Gastric Cancer.2016; 19: 1149-1150.
Kiso M, Yoshihara M, Ito M, Inoue K, Kato K, Nakajima S, Mabe K, Kobayashi M, Uemura N, Yada T, Oka M, Kawai T, Boda T, Kotachi T, Masuda K, Tanaka S and Chayama K. Characteristics of gastric cancer in negative test of serum anti-Helicobacter pylori antibody and pepsinogen test: a multicenter study. Gastric Cancer.2017; 20: 764-771.